Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The global market for women-specific cancers could reach $100 billion to $110 billion by 2030, according to a new PwC report. However, achieving that growth will require more than new investment. Pharmaceutical developers, diagnostic manufacturers and regulators must also close
Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion as the FDA introduces a clearer regulatory framework for psychedelic drug development. The deal adds the Phase III depression candidate BPL-003 to Lilly’s neuroscience pipeline. More importantly, the
GSK has stopped developing camlipixant for refractory chronic cough after mixed results from two Phase 3 trials. Although the drug met one primary endpoint in CALM-1, it failed the primary endpoint in CALM-2 and missed important secondary measures across both
Pharmaceutical manufacturing is entering a faster regulatory era. FDA is testing accelerated review models, companies are investing in artificial intelligence, and manufacturers are reconsidering where critical products should be produced. However, FDA’s latest quality data reveal an uncomfortable reality: faster
India’s life sciences sector has reached a critical turning point as local companies move beyond generics and develop novel drugs, CAR-T therapies, and AI-discovered molecules. However, a new report from Boston Consulting Group and HealthKois warns that weak clinical execution,
Novartis has secured full US FDA approval for Fabhalta in adults with primary immunoglobulin A nephropathy who are at risk of disease progression. The regulator converted the drug’s accelerated approval into a traditional approval after two-year phase 3 data showed
The European Medicines Agency (EMA) and the European Innovation Council and SMEs Executive Agency (EISMEA) strengthened their cooperation on July 15, 2026. Their new 2026–2027 work program will help European health innovators understand regulatory expectations earlier. The initiative matters because
Biogen has revealed mixed CELIA Phase II trial data for diranersen at AAIC 2026. The lowest 60 mg dose slowed clinical decline more than either 115 mg arm, although CELIA aimed to show greater benefit at higher doses. Consequently, the
Biogen has reported detailed results from the Phase 2 CELIA trial for diranersen (BIIB080) in early Alzheimer’s disease. The drug reduced tau and slowed cognitive decline across several measures. However, the lowest dose produced the strongest effect, so the study
The US Food and Drug Administration (FDA) has finalized its guidance for clinical trials involving psychedelic drugs. The document covers trial design, participant safety, abuse potential, data collection, and preclinical work. The FDA and the Department of Health and Human